Kardiorespirator tadqiqotlar jurnali 2022, №3
Subject of the article
CARDIOVASCULAR RISK FACTORS AND EXPRESSION LEVEL OF MICRORNA IN PATIENTS WITH MYOCARDIAL INFARCTION (37-42)
Authors
Edyta Nabiałek, Maciej Kaźmierski
Institution
Department of Cardiology and Structural Heart Diseases Medical University of Silesia
Abstract
Cardiovascular risk factors contribute to the development of cardiovascular disease and their presence may affect the level of microRNA expression in patients with ST-elevation myocardial infarction. So far, only a few reports have been published describing the relationship between microRNA expression and the presence of cardiovascular risk factors. Aim Evaluation of microRNA expression in patients with ST- elevation myocardial infarction with present cardiovascular risk factors. Materials & Methods Seventeen patients with ST-elevation myocardial infarction were examined. MicroRNA expression (miR-1, miR-208a i miR-423-5p) was determined according to the Pfaffla model and then compared between two groups: with and without cardiovascular risk factors. Results Higher expression levels of microRNAs were found in smokers. Lower levels of miR-1, miR-208a and miR-423-5p expression were found in patients with increased lipid levels or these using hypolipemic drugs. Conclusion MicroRNA expression in patients with ST-elevation myocardial infarction depends on the presence of some cardiovascular risk factors.
Key words
Cardiovascular risk factors, microRNA, myocardial infarction.
Literature
Mattick JS, Taft RJ, Faulkner GJ.. A global view of genomic information–moving beyond the gene and the master regulator. Trends Genet 2010;26:21–28. 2. Modrzejewski W, Musiał WJ. Stare i nowe czynniki ryzyka sercowo-naczyniowego – jak zahamować epidemię miażdżycy? Część I. Klasyczne czynniki ryzyka. Forum Zaburzeń Metabolicznych 2010; 1(2): 106-114. 3. Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et all. Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome. J Cardiovasc Trans Res 2013; 6: 884–898. 4. D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765–2773. 5. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res 2010; 106: 1035–1039. 6. Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013; 167: 531–536. 7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; J Am Coll Cardiol. 2012;60:1581-98. 8. The real-time polymerase chain reaction. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, et all. Mol Aspects Med. 2006;27:95-125. 9. Pfaffl MW. A new mathematical model for relative quantification In Real-time RT-PCR. Nucleic Acids Res 2001; 29: 2002–2007. 10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et all. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. 11. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et all. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34: 3035-87. 12. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et all. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012;33:1635-701. 13. Carroll AJ, Labarthe DR, Huffman MD, Hitsman B. Global tobacco prevention and control in relation to a cardiovascular health promotion and disease prevention framework: A narrative review. Prev Med. 2016;93: 189-197. 14. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C. et all. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477. 15. Piwońska A, Piotrowski W, Kozela M, Pająk A, Nadrowski P, Kozakiewicz K. et all. Cardiovascular diseases prevention in Poland: results of WOBASZ and WOBASZ II studies. Kardiol Pol. 2018;76:1534-1541. 16. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391: 73-77. 17. Long G, Wang F, Duan Q , Chen F, Yang S, Gong W, et all. Human Circulating MicroRNA-1 and MicroRNA-126 as Potential Novel Indicators for Acute Myocardial Infarction. Int J Biol Sci 2012; 8: 811––818. 18. Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su LX, Guo D, et all. Plasma Levels of microRNA-145 Are Associated with Severity of Coronary Artery Disease. PLoS One. 2015;10:e0123477. doi: 10.1371/journal.pone.0123477. eCollection 2015.